Last reviewed · How we verify

NCT01454843: LASIK

LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser

Completed Phase 4 Last updated 11 April 2022
What this trial tests

Phase 4 trial testing Wavefront-guided LASIK - Allegretto in Myopia in 60 participants. Completed in 23 June 2012.

Timeline
1 April 2009
Primary endpoint
31 March 2011
23 June 2012

Quick facts

Lead sponsorStanford University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 April 2009
Primary completion31 March 2011
Estimated completion23 June 2012
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 21 to 60, any sex, with Myopia or Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to compare the results of LASIK surgery when using Alcon Allegretto wavefront-guided excimer laser system compared to AMO Visx Custom wavefront-guided excimer laser system in patients with nearsightedness with and without astigmatism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01454843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing